Conservation Management of Tasmanian Devils in the Context of an Emerging, Extinction-threatening Disease: Devil Facial Tumor Disease

被引:0
|
作者
Menna E. Jones
Peter J. Jarman
Caroline M. Lees
Heather Hesterman
Rodrigo K. Hamede
Nick J. Mooney
Dydee Mann
Chrissy E. Pukk
Jemma Bergfeld
Hamish McCallum
机构
[1] University of Tasmania,School of Zoology
[2] Department of Primary Industries and Water,Wildlife Management Branch
[3] University of New England,School of Ecosystem Management
[4] Australasian Regional Association of Zoological Parks and Aquaria,undefined
[5] Diagnostic Services,undefined
[6] Department of Primary Industries and Water,undefined
来源
EcoHealth | 2007年 / 4卷
关键词
emerging wildlife disease; disease management; Tasmanian devil facial tumor disease; extinction risk; carnivorous marsupial; ecosystem impacts;
D O I
暂无
中图分类号
学科分类号
摘要
An emerging infectious facial cancer threatens Tasmanian devils with extinction. The disease is likely to occur across the range of the devil within 5 years. This urgent time frame requires management options that can be implemented immediately: the establishment of insurance populations, in captivity, wild-living on islands, and aiming for eradication in areas that can be isolated. The long-term options of the spontaneous or assisted evolution of resistance or development of a field-deliverable vaccine are unlikely to be available in time. The disease’s characteristic allograft transmission through intimate contact simplifies isolation of insurance populations and breaking transmission in suppression trials. Better knowledge of contact matrices in wild devils will help focus timing and demographic targets of removals. A metapopulation approach is needed that integrates captive and wild-living island and peninsula (disease suppression) populations to minimize the loss of genetic diversity over 50 years until either extinction and reintroduction can occur, resistance evolves or a field-deliverable vaccine is developed. Given the importance of the insurance populations and the low genetic diversity of devils, a conservative target for retention of 95% genetic diversity is recommended. Encouraging preliminary results of the first disease-suppression trial on a large peninsula show fewer late stage tumors and no apparent population decline. Limiting geographic spread or suppressing the disease on a broadscale are both unlikely to be feasible. Since the synergy of devil decline and impending fox establishment could have devastating consequences for Tasmanian wildlife, it is crucial to manage the dynamics of new and old predator species together.
引用
收藏
页码:326 / 337
页数:11
相关论文
共 50 条
  • [1] Conservation management of tasmanian devils in the context of an emerging, extinction-threatening disease: Devil facial tumor disease
    Jones, Menna E.
    Jarman, Peter J.
    Lees, Caroline M.
    Hesterman, Heather
    Hamede, Rodrigo K.
    Mooney, Nick J.
    Mann, Dydee
    Pukk, Chrissy E.
    Bergfeld, Jemma
    McCallum, Hamish
    [J]. ECOHEALTH, 2007, 4 (03) : 326 - 337
  • [2] Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease
    Phalen, David N.
    Frimberger, Angela
    Pyecroft, Stephen
    Peck, Sarah
    Harmsen, Colette
    Lola, Suzanneth
    Mattos, Beatriz de Mello
    Li, Kong M.
    McLachlan, Andrew J.
    Moore, Antony
    [J]. PLOS ONE, 2013, 8 (06):
  • [3] Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease
    Phalen, David N.
    Frimberger, Angela E.
    Peck, Sarah
    Pyecroft, Stephen
    Harmsen, Colette
    Lola, Suzanneth
    Moore, Antony S.
    [J]. VETERINARY JOURNAL, 2015, 206 (03): : 312 - 316
  • [4] The pathology of devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii)
    Loh, R.
    Bergfeld, J.
    Hayes, D.
    O'Hara, A.
    Pyecroft, S.
    Raidal, S.
    Sharpe, R.
    [J]. VETERINARY PATHOLOGY, 2006, 43 (06) : 890 - 895
  • [5] Tasmanian Devil facial tumor disease
    Vanherberghen, M.
    Desmecht, D.
    [J]. ANNALES DE MEDECINE VETERINAIRE, 2007, 151 (02) : 107 - 111
  • [6] Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils
    Peck, Sarah
    Corkrey, Ross
    Hamede, Rodrigo
    Jones, Menna
    Canfield, Paul
    [J]. VETERINARY CLINICAL PATHOLOGY, 2016, 45 (03) : 417 - 429
  • [7] Isotopic niche variation in Tasmanian devils Sarcophilus harrisii with progression of devil facial tumor disease
    Bell, Olivia
    Jones, Menna E.
    Cunningham, Calum X.
    Ruiz-Aravena, Manuel
    Hamilton, David G.
    Comte, Sebastien
    Hamede, Rodrigo K.
    Bearhop, Stuart
    McDonald, Robbie A.
    [J]. ECOLOGY AND EVOLUTION, 2021, 11 (12): : 8038 - 8053
  • [8] Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction
    McCallum, Hamish
    Jones, Menna
    Hawkins, Clare
    Hamede, Rodrigo
    Lachish, Shelly
    Sinn, David L.
    Beeton, Nick
    Lazenby, Billie
    [J]. ECOLOGY, 2009, 90 (12) : 3379 - 3392
  • [9] Distribution and impacts of Tasmanian devil facial tumor disease
    McCallum, Hamish
    Tompkins, Daniel M.
    Jones, Menna
    Lachish, Shelly
    Marvanek, Steve
    Lazenby, Billie
    Hocking, Greg
    Wiersma, Jason
    Hawkins, Clare E.
    [J]. ECOHEALTH, 2007, 4 (03) : 318 - 325
  • [10] Restoration of tumor immunosurveillance in tasmanian devil facial tumor disease
    Orlova, Anna
    Kosack, Lindsay
    Popa, Alexandra M.
    Viczenczova, Csilla
    Lercher, Alexander
    de Araujo, Elvin D.
    Gunning, Patrick
    Moriggl, Richard
    Bergthaler, Andreas
    [J]. CANCER RESEARCH, 2020, 80 (16)